Literature DB >> 31903610

PTPRε Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF-β Receptor 1.

Zhibin Liao1,2, Lin Chen1,2, Xuewu Zhang1,2, Hongwei Zhang1,2, Xiaolong Tan1,2, Keshuai Dong1,2, Xun Lu1,2, He Zhu1,2, Qiumeng Liu1,2, Zhanguo Zhang1,2, Zeyang Ding1,2, Wei Dong1,2, Peng Zhu1,2, Liang Chu1,2, Huifang Liang1,2, Pran K Datta3,4, Bixiang Zhang1,2,5,6,7, Xiaoping Chen1,2,5,6,7.   

Abstract

BACKGROUND AND AIMS: Transforming growth factor beta (TGF-β) suppresses early stages of tumorigenesis, but contributes to the migration and metastasis of cancer cells. However, the role of TGF-β signaling in invasive prometastatic hepatocellular carcinoma (HCC) is poorly understood. In this study, we investigated the roles of canonical TGF-β/mothers against decapentaplegic homolog 3 (SMAD3) signaling and identified downstream effectors on HCC migration and metastasis. APPROACH AND
RESULTS: By using in vitro trans-well migration and invasion assays and in vivo metastasis models, we demonstrated that SMAD3 and protein tyrosine phosphatase receptor epsilon (PTPRε) promote migration, invasion, and metastasis of HCC cells in vitro and in vivo. Further mechanistic studies revealed that, following TGF-β stimulation, SMAD3 binds directly to PTPRε promoters to activate its expression. PTPRε interacts with TGFBR1/SMAD3 and facilitates recruitment of SMAD3 to TGFBR1, resulting in a sustained SMAD3 activation status. The tyrosine phosphatase activity of PTPRε is important for binding with TGFBR1, recruitment and activation of SMAD3, and its prometastatic role in vitro. A positive correlation between pSMAD3/SMAD3 and PTPRε expression was determined in HCC samples, and high expression of SMAD3 or PTPRε was associated with poor prognosis of patients with HCC.
CONCLUSIONS: PTPRε positive feedback regulates TGF-β/SMAD3 signaling to promote HCC metastasis.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID: 31903610     DOI: 10.1002/hep.31104

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

1.  Chondroitin polymerizing factor predicts a poor prognosis and promotes breast cancer progression via the upstream TGF-β1/SMAD3 and JNK axis activation.

Authors:  Qiang-Feng Pan; Wei-Wei Ouyang; Meng-Qi Zhang; Shuo He; Si-Yun Yang; Jun Zhang
Journal:  J Cell Commun Signal       Date:  2022-08-30       Impact factor: 5.908

2.  Chaperone-mediated Autophagy Regulates Cell Growth by Targeting SMAD3 in Glioma.

Authors:  Hanqun Liu; Yuxuan Yong; Xingjian Li; Panghai Ye; Kai Tao; Guoyou Peng; Mingshu Mo; Wenyuan Guo; Xiang Chen; Yangfu Luo; Yuwan Lin; Jiewen Qiu; Zhiling Zhang; Liuyan Ding; Miaomiao Zhou; Xinling Yang; Lin Lu; Qian Yang; Pingyi Xu
Journal:  Neurosci Bull       Date:  2022-03-10       Impact factor: 5.271

3.  circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling.

Authors:  Jiang Zhu; Yuming Luo; Yue Zhao; Yao Kong; Hanhao Zheng; Yuting Li; Bowen Gao; Le Ai; Hao Huang; Jian Huang; Zhihua Li; Changhao Chen
Journal:  Mol Ther       Date:  2021-02-03       Impact factor: 11.454

4.  Inhibition of long noncoding RNA cancer susceptibility candidate 7 attenuates hepatocellular carcinoma development by targeting microRNA-30a-5p.

Authors:  Dongsheng Li; Lin Lu; Miaomiao Liu; Jufeng Sun
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 5.  Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy.

Authors:  Jitang Chen; Ze-Yang Ding; Si Li; Sha Liu; Chen Xiao; Zifu Li; Bi-Xiang Zhang; Xiao-Ping Chen; Xiangliang Yang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

6.  miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE.

Authors:  Bingqing Chen; Zhibin Liao; Yongqiang Qi; Hongwei Zhang; Chen Su; Huifang Liang; Bixiang Zhang; Xiaoping Chen
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

7.  GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma.

Authors:  Qian Yun Ge; Jin Chen; Gan Xun Li; Xiao Long Tan; Jia Song; Deng Ning; Jie Mo; Peng Cheng Du; Qiu Meng Liu; Hui Fang Liang; Ze Yang Ding; Xue Wu Zhang; Bi Xiang Zhang
Journal:  Clin Transl Med       Date:  2021-11

8.  Identification of a TGF-β/SMAD/lnc-UTGF positive feedback loop and its role in hepatoma metastasis.

Authors:  Meng-Zhi Wu; Yi-Chuan Yuan; Bi-Yu Huang; Jin-Xi Chen; Bin-Kui Li; Jian-Hong Fang; Shi-Mei Zhuang
Journal:  Signal Transduct Target Ther       Date:  2021-11-17

Review 9.  Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma.

Authors:  Daisuke Uchida; Akinobu Takaki; Atsushi Oyama; Takuya Adachi; Nozomu Wada; Hideki Onishi; Hiroyuki Okada
Journal:  Nutrients       Date:  2020-05-28       Impact factor: 5.717

10.  MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner.

Authors:  Zhao Huang; Jingyuan Wen; Jingjing Yu; Jingyu Liao; Sha Liu; Ning Cai; Huifang Liang; Xiaoping Chen; Zeyang Ding; Bixiang Zhang
Journal:  J Exp Clin Cancer Res       Date:  2020-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.